{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-21-005791","form_type":"8-K","ticker":"PMDI","cik":"0000806517","company_name":"PSYCHEMEDICS CORP","filed_at":"2021-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:20.807027+00:00","generated_at":"2026-06-29T17:35:44.299462+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Psychemedics Q2 2021 revenue up 85% to $6.1M, swings to net income of $0.1M","bullets":["Revenue $6.1M vs $3.3M in Q2 2020 (+85%); net income $0.1M ($0.02 EPS) vs net loss $2.1M (-$0.37).","Domestic revenue up ~80%, driven by Oil & Gas, Manufacturing, Transportation segments; international revenue up 153% on small base.","Recorded $0.8M employee retention tax credit (ERC) under CAA; expects eligibility for Q3 and Q4 2021.","PPP loan of $2.2M fully forgiven by SBA in July 2021; cash $2.7M, working capital $7.1M as of June 30.","Dividend remained suspended since Q1 2020; board continues to evaluate quarterly."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-21-005791","json":"https://secwatch.observer/filing/0001171843-21-005791.json","markdown":"https://secwatch.observer/filing/0001171843-21-005791.md","text":"https://secwatch.observer/filing/0001171843-21-005791.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/806517/000117184321005791/0001171843-21-005791-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/806517/000117184321005791/f8k_081021.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T17:35:44.299462+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}